PT3177632T - Pró-fármacos do inibidor de antígeno de membrana específica da próstata (psma) - Google Patents

Pró-fármacos do inibidor de antígeno de membrana específica da próstata (psma)

Info

Publication number
PT3177632T
PT3177632T PT158292151T PT15829215T PT3177632T PT 3177632 T PT3177632 T PT 3177632T PT 158292151 T PT158292151 T PT 158292151T PT 15829215 T PT15829215 T PT 15829215T PT 3177632 T PT3177632 T PT 3177632T
Authority
PT
Portugal
Prior art keywords
psma
prodrugs
inhibitor
prostate specific
specific membrane
Prior art date
Application number
PT158292151T
Other languages
English (en)
Original Assignee
Univ Johns Hopkins
Inst Of Organic Chemistry And Biochemistry As Cr V V I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Inst Of Organic Chemistry And Biochemistry As Cr V V I filed Critical Univ Johns Hopkins
Publication of PT3177632T publication Critical patent/PT3177632T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4071Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075Esters with hydroxyalkyl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4071Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4084Esters with hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4071Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4087Esters with arylalkanols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • C07F9/4461Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4465Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT158292151T 2014-08-06 2015-08-06 Pró-fármacos do inibidor de antígeno de membrana específica da próstata (psma) PT3177632T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462033926P 2014-08-06 2014-08-06

Publications (1)

Publication Number Publication Date
PT3177632T true PT3177632T (pt) 2022-03-21

Family

ID=55264571

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158292151T PT3177632T (pt) 2014-08-06 2015-08-06 Pró-fármacos do inibidor de antígeno de membrana específica da próstata (psma)

Country Status (14)

Country Link
US (4) US9988407B2 (pt)
EP (1) EP3177632B1 (pt)
CA (1) CA2961880C (pt)
CY (1) CY1125201T1 (pt)
DK (1) DK3177632T3 (pt)
ES (1) ES2908411T3 (pt)
HR (1) HRP20220446T1 (pt)
HU (1) HUE058072T2 (pt)
LT (1) LT3177632T (pt)
PL (1) PL3177632T3 (pt)
PT (1) PT3177632T (pt)
RS (1) RS63082B1 (pt)
SI (1) SI3177632T1 (pt)
WO (1) WO2016022827A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4374924A2 (en) 2013-10-18 2024-05-29 Novartis AG Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10172873B2 (en) * 2014-08-06 2019-01-08 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
LT3177632T (lt) 2014-08-06 2022-04-25 The Johns Hopkins University Prostatos specifinio membraninio antigeno (psma) inhibitoriaus provaistai
JP2020530007A (ja) * 2017-04-11 2020-10-15 ザ・ジョンズ・ホプキンス・ユニバーシティ Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2−pmpaのプロドラッグ
GB201810965D0 (en) * 2018-07-04 2018-08-15 Univ College Cardiff Consultants Ltd Phosphoantigen prodrug compounds
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
US20210323985A1 (en) * 2018-09-21 2021-10-21 Endocyte, Inc. Shielding agents and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
DE60238435D1 (de) 2001-10-26 2011-01-05 Scripps Research Inst Gezielte thrombose durch gewebefaktor polypeptiden
US20060046978A1 (en) 2004-08-31 2006-03-02 Morphochem Ag Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
US10172873B2 (en) * 2014-08-06 2019-01-08 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
LT3177632T (lt) * 2014-08-06 2022-04-25 The Johns Hopkins University Prostatos specifinio membraninio antigeno (psma) inhibitoriaus provaistai

Also Published As

Publication number Publication date
LT3177632T (lt) 2022-04-25
US11932664B2 (en) 2024-03-19
CY1125201T1 (el) 2024-02-16
US20200399298A1 (en) 2020-12-24
HUE058072T2 (hu) 2022-07-28
CA2961880A1 (en) 2016-02-11
US20170226141A1 (en) 2017-08-10
EP3177632A4 (en) 2018-04-04
ES2908411T3 (es) 2022-04-29
US10544176B2 (en) 2020-01-28
US20230115651A1 (en) 2023-04-13
DK3177632T3 (da) 2022-03-21
US20180244705A1 (en) 2018-08-30
HRP20220446T1 (hr) 2022-05-27
RS63082B1 (sr) 2022-04-29
CA2961880C (en) 2022-09-27
PL3177632T3 (pl) 2022-06-13
US11325931B2 (en) 2022-05-10
WO2016022827A1 (en) 2016-02-11
SI3177632T1 (sl) 2022-05-31
US9988407B2 (en) 2018-06-05
EP3177632B1 (en) 2022-01-12
EP3177632A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
PH12016501922A1 (en) Substituted spirocyclic inhibitors of autotaxin
GB201407267D0 (en) Underwater surveys
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
PT3177632T (pt) Pró-fármacos do inibidor de antígeno de membrana específica da próstata (psma)
IN2015DE00625A (pt)
GB201405235D0 (en) Improved plumbing apparatus
GB201401005D0 (en) Inhibitor
GB2541309B (en) Musical instruments
IN2014MU03184A (pt)
GB201417347D0 (en) Prodrugs of delanzomib
GB201417348D0 (en) Prodrugs of lxazomib
IN2014CH00927A (pt)
GB201418154D0 (en) Inhibitors
GB201415292D0 (en) Musical instruments
GB201403344D0 (en) Music
GB201411017D0 (en) Musical instruments
GB201402839D0 (en) Music teaching aid